Hector Cerna Aguila
About Hector Cerna Aguila
Hector Cerna Aguila is a Lab Operations Specialist at JSat Automation Inc, where he has worked since 2022. He has a background in biotechnology and has held various roles in research and quality assurance, contributing to significant projects in equipment calibration and environmental monitoring.
Work at JSat Automation
Hector Cerna Aguila has been employed at JSat Automation Inc as a Lab Operations Specialist since 2022. In this role, he serves as a subject matter expert for SAP, where he is responsible for implementing changes and updates. He also provides guidance and training to other departments, ensuring that operational standards are met.
Previous Experience at CSL Behring
Prior to his current position, Hector worked at CSL Behring as a Research Assistant from 2021 to 2022 for a duration of 10 months in Pasadena, California. During his tenure, he rolled out Master Inspection Characteristics for site-wide equipment calibrations, which ensured proper validation of metrology activities in SAP. He also implemented the design and installation of a new Environmental Monitoring System across CSL laboratories.
Background in Stem Cell Science
Hector's career includes a brief role at Pathways to Stem Cell Science in 2021, where he worked for one month in Torrance, California. This experience contributed to his knowledge in the field of biotechnology and stem cell research.
Education and Expertise
Hector Cerna Aguila holds a Bachelor of Science degree in Biotechnology from California State University, Northridge. His educational background has equipped him with the necessary skills and knowledge to excel in laboratory operations and research environments.
Contributions to Quality Assurance
Throughout his career, Hector has collaborated with local and global Quality Assurance teams. He has utilized Quality Management Systems for audits, assessments, SOP revisions, and global change controls. Additionally, he led efforts to harmonize local and global engineering standards for CSL's developing gene therapy site.